CDER’s new proposal to withdraw the accelerated acceptance of Makena (HPC) was based mostly upon a big randomized trial that failed to verify the good thing about this drug to newborns or minimize the risk of PTB. In earning the decision to suggest Makena’s withdrawal, CDER also reviewed outcomes from prior reports of progestins (HPC along wi